Vitiligo

In a Dermatology Times Case-Based Roundtable event, Pearl E. Grimes, MD, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib.

In a Dermatology Times Case-Based Roundtable event, Ted Lain, MD, MBA, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib.

Studies show conflicting serum levels of zinc and copper in vitiligo patients, indicating a need for further research.

In a Dermatology Times Case-Based Roundtable event, Chesahna Kindred, MD, MBA, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib cream.

Investigators noted that further research is needed to monitor the prevalence of cardiovascular disease in patients with vitiligo.

In a Dermatology Times Case-Based Roundtable event, Andrew Alexis, MD, MPH, FAAD, reviewed 3 cases of patients with vitiligo treated with ruxolitinib cream.

A review examined how vitiligo treatments aim to restore melanocyte function through grafting, phototherapy, immune regulation, antioxidants, and stem cell research.

Researchers behind the review suggested that future research should prioritize large-scale trials to confirm abrocitinib's long-term safety and efficacy in various skin disorders.

Researchers found that MBEHQ treatment increased oxidative stress and proinflammatory cytokines IL-1β and IL-18 in patients with vitiligo.

Catch up on the latest news on vitiligo advancements in 2024.

The study is actively recruiting participants at multiple sites across the US.

The study showed significant improvement in repigmentation with silymarin, with patients of different sexes benefiting equally, though monthly differences were not significant.

The 83-year-old patient was being treated for mycosis fungoides.

42 studies with 1027 cases evaluated drugs like bimatoprost and apremilast for vitiligo.

Researchers identified KLB and EIF3C as potential biomarkers for vitiligo and AA, offering new targets for early diagnosis and treatment.

Learn more about the in-depth topics covered in the August 2024 supplement of Dermatology Times.

At the conclusion of their roundtable event, Rocco Serrao, MD, FAAD; Latanya Benjamin, MD, FAAD; and Anthony Nuara, MD, PhD, discuss final considerations for tailoring vitiligo treatment plans.

Anthony Nuara, MD, PhD, reviewed a case study of a 32-year-old professional makeup artist who was concerned about her depigmented patches affecting her livelihood.

Latanya Benjamin, MD, FAAD, reviewed a case study of a 35-year-old woman with a 10-year history of vitiligo and concomitant atopic dermatitis

Rocco Serrao, MD, FAAD, reviewed a case study of a 20-year-old man with segmental vitiligo and the psychological impact of his vitiligo.

The findings highlight the need for diverse genetic studies to understand their broader impact on autoimmune diseases.

Skin with vitiligo and psoriasis shows increased immune cell type, with a Mendelian analysis finding no causal link between the conditions.

Naiem Issa, MD, PhD, shared highlights from his sessions on the 1726 nm laser for acne, atopic dermatitis disease modification, advances in hidradenitis suppurativa, and microneedling techniques for vitiligo.

Iltefat Hamzavi, MD, discusses the REGINA 007 phase 2 trial evaluating MK-6194 for the treatment of non-segmental vitiligo.

Researchers examined the role of diabetes and glycemic profile in the risk of development of vitiligo in a Mendelian randomization study.

Researchers said individuals with vitiligo should monitor for RA and SLE, as regular check-ups are essential for managing this risk.

David Rosmarin, MD, shared his insights on the study in a Q&A with Dermatology Times.

Silverberg discusses her SPD 2024 lecture, "Approach to Progressive Vitiligo," the future vitiligo landscape, and more.

Walter Liszewski, MD, shares insights into discrepancies between permanent makeup and decorative tattoos and which patients may benefit from permanent makeup.

The treatment of vitiligo has advanced from ancient herbal remedies to the first FDA-approved topical, paving the way for improved management and outcomes.